Medable introduces Digital Data Flow agent, laying the foundation for end-to-end agentic clinical development. New agent supports digital infrastructure needed for FDA's emerging real-time clinical trial model PALO ALTO, Calif.-(BUSINESS WIRE)-Medable Inc., the leading technology platform for agentic clinical development, today announced its Digital Data Flow (DDF) Agent, which automatically transforms static clinical trial protocols into structured, machine-readable data that can be continuously used across the clinical development lifecycle. Traditionally, clinical trial protocols are static documents that require extensive manual interpretation and re-creation across many downstream systems. Medable's DDF Agent converts protocol information into a CDISC USDM 4.0, standardized, structured JSON data format, which is foundational for automated and dynamic readiness and adaptivity throughout a clinical trial. For example, using Medable's DDF Agent, trial sponsors can automatically generate their electronic clinical outcomes assessments (eCOAs) in minutes, while maintaining alignment with the source protocol and any subsequent amendments. As the industry moves toward more adaptive and real-time data clinical trial models, Medable's DDF Agent helps establish the infrastructure needed for continuous protocol evolution. Changes made to the protocol after approval can automatically propagate across connected documents, workflows, and systems, reducing operational burden and helping organizations respond more rapidly to emerging study insights. This approach aligns with the U.S. Food and Drug Administration's vision for real-time clinical trials, where ongoing data review becomes standard practice. In such an environment, maintaining consistency across study documentation and operational systems will require a digital, machine-readable foundation rather than traditional, document-based processes. Medable's DDF Agent represents an important step toward enabling that future. "The FDA's move toward real-time clinical trials makes clear that the industry can no longer rely on static documents and manual handoffs to support modern study execution," said Jessica Dolfi, Medable Senior Vice President of Solution Consulting. "Medable's DDF Agent helps create the machine-readable foundation needed to keep protocols, downstream systems, and operational workflows continuously aligned. That is essential for a future in which study data, endpoints, and safety signals must move with greater speed, consistency, and traceability to support real-time trial execution and responsiveness." Medable is agentifying the clinical development lifecycle, from protocol initiation to study close-out with Medable Agent Studio - a purpose-built agentic AI platform for clinical development that enables sponsors and CROs to deploy AI agents across clinical workflows. The platform combines no-code agent creation, human-in-the-loop oversight, GxP-ready compliance controls, a clinical data ontology layer, built-in AI governance, and Model Context Protocol connectors across clinical and enterprise systems to automate operational work while maintaining transparency, auditability, and regulatory alignment. And Medable's Agentic Accelerator Program with onboarding, integration support, and change management allows customers to gain value from AI agents on day one. About Medable Medable is on a mission to get effective therapies to people faster. Its agentic clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Leader in eCOA by Everest Group, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Learn more at medable.com. Contacts. Media Contact Lisa Barbadora, Barbadora INK for Medable +1 (610) 420-3413 [email protected] / [email protected] More News From Medable Inc. PALO ALTO, Calif.-( BUSINESS WIRE )-Medable Inc., the leading technology platform for agentic AI-powered clinical development, today announced its Agentic Accelerator Program to help life sciences companies transform clinical development with agentic AI. The program includes onboarding, integration support, governance, and change management to enable sponsors and contract research organizations to gain value from AI agents from day one. Surprisingly, only 22% of life sciences leaders have scale... PALO ALTO, Calif.-( BUSINESS WIRE )-Medable Inc., the leading technology platform for agentic AI clinical development, today announced that its CEO and co-founder, Dr. Michelle Longmire, will be one of three international guest speakers at Japan's largest pharmaceutical conference, Ubie Pharma Summit (May 13-14, 2026). Longmire will be speaking at the fifth annual event along with Justin Chen, MD, Clinical Specialist at Google for Health, and John Halamka, MD, President of Mayo Clinic Platform... PALO ALTO, Calif.-( BUSINESS WIRE )-Medable Inc., the leading technology platform for AI-powered clinical development, today launched Agentic AI for research sites to reduce burden and assist principal investigators (PIs) in oversight and monitoring of electronic clinical outcome assessment (eCOA) data. Medable's newest agent integrates seamlessly within its eCOA system workflows. Released just after Medable's TMF and CRA agents, its PI Summary Agent continues the company's rapid rollout of fun...

Medable has launched its Agentic Accelerator Program to help life sciences companies deploy agentic AI across clinical development. The programme provides onboarding, integration support, governance and change management to enable sponsors and contract research organisations to gain value from AI agents immediately. Currently, only 22% of life sciences leaders have scaled AI across their enterprises. The programme offers strategic guidance and implementation support through dedicated AI clinical development experts and forward-deployed engineers, enabling customers to quickly deploy standard agentic use cases whilst developing proprietary workflows on Medable's platform. The initiative supports Medable Agent Studio, a purpose-built agentic AI platform for clinical development featuring no-code agent creation, human-in-the-loop oversight, GxP-ready compliance controls and built-in AI governance. Medable's platform has been deployed in nearly 400 trials across 70 countries.

Medable, a clinical development technology platform, has launched an AI agent to assist principal investigators with oversight of electronic clinical outcome assessment data at research sites. The PI Summary Agent continuously monitors participant eCOA data, generating summaries and highlighting critical data points whilst maintaining human oversight. The agent addresses regulatory requirements for oversight of remotely captured data, which traditionally required manual verification across multiple systems. It centralises participant data inputs to streamline remote monitoring without disrupting trial operations. Released following Medable's TMF and CRA agents, the new capability is available now as part of Medable's eCOA platform. The company's platform has been deployed in nearly 400 trials across 70 countries, serving over one million patients globally.